About

Our Mission

Cansera is an AI-driven biotechnology startup focused on unlocking digital biomarkers from routine blood tests to transform cancer care. Our mission is to bridge cutting-edge machine learning with translational oncology, enabling earlier detection of cancer and more personalized treatments through advanced analysis of rare cells.

The Challenge in Cancer Detection

Each year, millions of lives are lost to cancer, in part because diagnosis often comes too late. For example, ~95% of multiple myeloma cases are only caught at advanced stages, and up to 40% of early-stage breast cancer patients still relapse despite initial treatment. These sobering statistics highlight an urgent need to detect cancer earlier and monitor it more accurately. Traditional tissue biopsies and scans can miss microscopic disease. However, emerging liquid biopsy approaches – analyzing cancer signals from a simple blood draw – offer a minimally invasive way to find cancer biomarkers sooner. The challenge is that truly informative signals in blood (like circulating tumor cells or other rare tumor-related cells) are extremely scarce (often <1 in a million blood cells). Until now, identifying these rare cells required painstaking manual reviews or tests targeting known markers, limiting both the scale and scope of discovery.

Democratizing Liquid Biopsy Analytics

Cansera was founded to overcome this limitation by harnessing artificial intelligence to automatically hunt for those one-in-a-million cells. We developed a software platform that uses advanced machine learning to analyze entire blood samples without preselecting what to look for. By removing the need for highly trained human technicians to manually scan slides, we make rare-cell detection scalable and unbiased. Our cloud-based tool can process huge digital microscopy datasets and discover abnormal cells that traditional methods might overlook – all in a standardized, reproducible workflow. In other words, we are replacing labor-intensive human review with reproducible AI, opening up sophisticated blood analysis to any lab with a scanner. This democratized approach allows research teams worldwide to explore new cellular biomarkers and test hypotheses that were previously impractical due to technical barriers.

From Research to Real-World Impact

Our vision is to translate these innovations into tangible improvements in patient care. By enabling global, data-driven analysis of rare cells, we aim not only to advance early cancer detection but to reshape how diagnostics are designed and how therapies are guided. Insights from Cansera’s platform could help doctors catch relapse signs months earlier, or identify which tiny subset of cells is driving a patient’s tumor growth – information that can inform personalized treatment decisions. We are actively collaborating with leading cancer research centers to validate our technology on real clinical samples, ensuring it performs reliably across different hospitals and patient populations. Ultimately, Cansera is committed to bridging the gap between laboratory breakthroughs and clinical practice. By focusing on robust engineering and rigorous validation, we’re accelerating the translation of AI-powered diagnostics into everyday oncology. Our mission is to provide clinicians and researchers a powerful new lens on cancer – one that can reveal critical cellular “needle in the haystack” signals from a simple blood test, in time to make a life-saving difference.